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High-throughput, high-quality genome sequencing is becoming 
increasingly accessible as a result of advances in sequencing 
technology and analytical capacity, and reduced cost. Coupled with 
rapid advances in genome engineering, this increased accessibility is 
driving the creation of novel and highly efficacious medicines that 
are changing the way in which we practise. The recent introduction 
of chimeric antigen receptor T (CAR T)-cells for certain leukaemias 
and lymphomas is a case in point.[1] One of the two products 
currently available was tested in a clinical trial that involved minors;[2] 
nevertheless, many ethical and legal issues pertaining to this patient 
group remain unresolved. Many medicines are used off label for 
children, especially older drugs and antibiotics, on the basis of 
extrapolation of clinical trial data from adults to children. However, 
this practice is ethically and scientifically questionable, especially for 
very young children, because children are physiologically different 
from adults and safety profiles of medicines may be different too. 
Consequently, it is important that as the number of clinical trials 
in the cell and gene therapy field increases, minors are included to 
ensure that they too benefit from these therapies.
The regulatory landscape
Minors are protected by the law from their limited life experience 
and their own emotional, cognitive and physical immaturity. Section 
71 of the National Health Act No. 61 of 2003 (NHA)[3] stipulates 
specific requirements for their participation in research. These are 
described in the National Department of Health’s Ethics in Health 
Research Guidelines (DoH 2015),[4] in which minors are considered 
a vulnerable population for which various regulatory requirements 
and considerations pertain so as to ensure appropriate protection 
from risk of harm. This means inter alia that the safety profile of 
new medicines should at least be known to a reasonable extent 
before clinical trials are conducted to test new therapies with minors. 
Further, the ethical approach is to adopt a phased introduction of 
new medicines. This serves to mitigate the probability and magnitude 
of risk of harm to younger minors. Before children below puberty 
are included in clinical trials, cell and gene therapies should have 
been tested with adults and then with older minors (adolescents) so 
that knowledge of the safety profile in humans at various stages of 
development increases incrementally. The principles of cell therapy 
in children v. adults have not been established clearly. For example, 
their effects on growth and development are unknown. Adopting the 
developmentally phased approach that tests adults and then older 
minors before younger minors is likely to assist in clarifying these 
principles.
The South African (SA) regulatory framework requires that all 
research (including new cell and gene therapies) in minors (persons 
aged <18 years) only be conducted with the consent of the parent or 
guardian of the minor, and if the minor is capable of understanding, 
with the consent of the minor. Voluntariness of the choice to 
participate in research on malignancies in minors may cause a sense 
of desperation, especially for the parents. Such emotions may increase 
vulnerability and may therefore affect the informed consent process. 
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For example, a feeling of desperation may change a ‘small’ chance of 
benefit into a ‘reasonable’ chance.
The DoH 2015[4] guidelines explain the informed consent require-
ments for minors (section 3.2.2) as well as how to manage innovative 
therapies or experiments (section 3.5.1). The overarching principle is 
that involving minors in research to test the use of an innovative cell 
or gene therapy should not be against the best interests of that minor 
(section 3.2.2). This is especially significant when adult data are used 
to inform research designs for trials with minors.
Research v. innovative therapies
An important distinction is drawn in the DoH 2015[4] guidelines 
between research and innovative treatment. The possibility of using 
cell or gene therapy may be presented in either form. The primary 
distinction lies in the purpose of each. Research pursues generalisable 
knowledge for the benefit of future patients where the therapeutic 
best interests of a particular individual is not the main aim of the 
study. On the other hand, innovative treatment, while using the same 
product, is focused on the single recipient and all actions should 
therefore be carried out in the best interests of the particular minor.
This distinction has bearing on the minimum age that is legally 
required for giving informed consent. A minor is defined as anyone 
below the age of 18 years. For research, in principle, all minors must 
be assisted with informed consent. For treatment, on the other hand, 
the Children’s Act No. 38 of 2005[5] creates exceptions to the general 
rule that minors may not make significant decisions without the 
assistance of a parent or guardian. Among others, it provides that 
a minor older than 12 years may consent to medical treatment if 
sufficiently mature and appropriately informed. However, great 
caution should be exercised regarding innovative treatment to 
prevent undue influence on a young sick person. Considering 
the gravity of the decision, we contend that for minors older than 
12 years of age the ethical stance should be, even if not (yet) strictly 
required by law, that parents, guardians or caregivers must be 
involved in the discussions and decision-making. Minors younger 
than 12 years must also be included in discussions and decisions 
about their health in so far as their capacity allows (see section 129 
of the Children’s Act[5]). The decision to proceed must be based on a 
reasonable chance that the intervention may work in the minor, in 
light of the adult and/or adolescent data available (see DoH 2015[4] 
Appendix 3, ‘Novel, innovative or unproven treatment’).
Individual-specific factors are fundamental when cell or gene 
therapies are being considered in the context of a clinical trial or 
an innovative therapy. The clinical status of the participants, the 
effects of prior and concurrent treatments, cell collection risks, and 
variability in cellular starting material and the manufacturing process 
are therefore all significant. Also important are ethical considerations 
related to process failures in the production of a complete therapeutic 
dose of, for example, gene-modified T-cells. Failure could be due 
to inadequate T-cell harvests, poor gene modification rates or poor 
CAR T-cell expansion. The information provided in the informed 
consent documentation must include these possible outcomes, as 
they are directly relevant when making a decision about whether to 
participate.
Conducting a clinical trial using cell and gene therapy therefore 
requires consideration of numerous product-related factors that 
will influence patient and trial outcomes, and cell preparations 
should meet strict criteria at each step. In the case of gene-
engineered T-cell therapies, such as CAR T-cells, these factors 
include apheresis collection of T-cells, where adequate cell numbers 
need to be harvested; gene transfer/engineering rates, which tend 
to vary between patients; and T-cell expansion, which also varies 
from sample to sample. Specific issues that must be considered for 
children include the onerous nature of cell harvesting – apheresis is 
an invasive and time-consuming procedure. Additionally, the labour-
intensive manufacturing processes, as well as an increased likelihood 
of obtaining suboptimal yields relative to those obtained in the adult 
population, need to be considered.
If the yield of the therapeutic product post manufacturing is 
suboptimal but all other quality control standards are met, two 
options may be envisaged: the samples are excluded and the treatment 
is abandoned, or patients are still treated but stratified into a separate 
analysis group. Weighing up the levels of risk of harm against the 
likelihood of benefit is very important in determining what may 
be in the best interests of the individual minor. Given the onerous 
nature of cell harvesting in children, the labour-intensive nature of 
manufacturing and the expectations created in the patient and her/
his family, the latter, i.e. stratification into a separate analysis group, 
might be more appropriate.
The NHA[3] provides for innovative or experimental treatment 
(section 11) and requires that, prior to treatment, the patient must 
be informed of the experimental or innovative status of the intended 
treatment (see also DoH 2015,[4] section 3.5.1 and Appendix 3). 
However, this decision involving the minor with the parents or 
guardian should be made with the involvement of several clinicians 
rather than a single clinician, considering the many implications and 
the gravity of the decision. Also, a properly described risk-benefit 
decisional analysis schema should be used. Once clinically warranted 
to offer the innovative treatment to the minor patient, the informed 
consent process is subject to the general requirements of informed 
consent as applicable to other interventions regarding, for example, 
provision of sufficient and adequate information as well as time in 
which to deliberate and choose.
The distinction between research and innovative treatment should 
also be applied in the case of individual use of cell and gene therapies. 
If the purpose is research, a research ethics committee registered with 
the National Health Research Ethics Council must review and decide 
whether to approve it. If it is experimental treatment for a specific 
patient rather than research, it is ethically appropriate for a clinical 
ethics committee (CEC) to review the available data including the 
potential risk of harm and the likelihood of benefit, even though this 
is not currently a legal requirement (see DoH 2015,[4] Appendix 3). In 
SA, few standing CECs exist and their requirements are not regulated 
at this time. A significant consideration is that no insurance cover for 
treatment of bodily injury suffered by the patient would be available 
for experimental treatment as it would be for a research participant. 
The potential use of CAR T-cell therapies with minors underscores 
the desirability of establishing CECs, which should have an oversight 
role in all matters pertaining to the innovative or experimental 
treatment, including the informed consent documentation. The 
nature of a desirable structure for CECs should be discussed, e.g. 
whether there should be institutional CECs or regional CECs. These 
may help to establish a database for reporting on experimental 
treatment, by which to inform future use and trials.
Regulatory frameworks in other 
jurisdictions
The development of cell and gene therapies for child populations in 
Europe is subject to provisions of the European Medicine Agency, 
which ‘has a number of important tasks and responsibilities relating 
to the development of paediatric medicines. These responsibilities, 
granted through the European Union (EU) Paediatric Regulation, 
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enable the Agency to stimulate research into the uses of medicines 
in children and to lead to their authorisation in all age groups.’[6] 
An important part of this process involves the development of a 
Paediatric Investigation Plan  which is aimed at ‘ensuring that the 
necessary data are obtained through studies in children, to support 
the authorisation of a medicine for children’.[7]
In the USA, the Food and Drug Administration (FDA) regulates 
the use of medicines in children through the Best Pharmaceuticals for 
Children Act (BPCA) and Pediatric Research Equity Act (PREA). [8] 
‘The Pediatric Research Equity Act originally was passed in 2003. 
PREA requires pharmaceutical companies to assess the safety and 
effectiveness of new drug and biologic products in pediatric patients. 
BPCA was passed in 2002. BPCA provides a financial incentive 
to pharmaceutical companies to test drugs with remaining patent 
life in pediatric patients. In addition, this Act creates a process by 
which FDA and the National Institutes of Health (NIH) can partner 
to obtain studies of off-patent drugs in pediatric patients. A key 
difference between the laws is that PREA is a mandatory law and 
BPCA is voluntary.’[9]
Benefits v. risks
Finally, after more than two decades, gene therapy is proving to 
be beneficial for a number of disorders. This includes primary 
immunodeficiency, sickle cell disease, haemophilia, haematological 
malignancies, retinal disorders and dermatological disorders such 
as epidermolysis bullosa.[10,11] However, as is the case with most 
pharmaceuticals, benefits need to be weighed against risks for 
cell and gene therapies, which fall under the ambit of biological 
medicines in SA.[12] The case of Jesse Gelsinger, who was 18 when he 
died as a result of his immune system’s reaction to the viral vector 
used to introduce a functional copy of an enzyme his body lacked, 
is a sober reminder of the factors that need to be considered.[13] 
Likewise, a recent publication[14] has reported a greater number of 
off-target effects of the CRISPR-Cas9 gene editing technique than 
had previously been identified. However, given the potential benefits 
to be derived from these innovative therapies and the rigour to which 
their application and manufacture are being subjected, it is likely that 
the potential drawbacks mentioned (and others) will be able to be 
managed to minimise risk to the patients concerned.
Conclusions
New cell and gene therapies, including novel cancer therapies such 
as CAR T-cells, raise the question of how best to introduce these 
innovations to assist child patients. We suggest that clinical trials 
of promising innovative therapies should be conducted as per the 
responsible testing described above. The clinical trials in minors 
should be conducted as soon as possible, averting the need for, and 
risks of, experimental therapeutic use of cell and gene therapies 
on an individual basis. If these trials suggest that the therapies are 
efficacious and safe, they can be approved for use.
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